Literature DB >> 19783980

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

Mark A Dawson1, Andrew J Bannister, Berthold Göttgens, Samuel D Foster, Till Bartke, Anthony R Green, Tony Kouzarides.   

Abstract

Activation of Janus kinase 2 (JAK2) by chromosomal translocations or point mutations is a frequent event in haematological malignancies. JAK2 is a non-receptor tyrosine kinase that regulates several cellular processes by inducing cytoplasmic signalling cascades. Here we show that human JAK2 is present in the nucleus of haematopoietic cells and directly phosphorylates Tyr 41 (Y41) on histone H3. Heterochromatin protein 1alpha (HP1alpha), but not HP1beta, specifically binds to this region of H3 through its chromo-shadow domain. Phosphorylation of H3Y41 by JAK2 prevents this binding. Inhibition of JAK2 activity in human leukaemic cells decreases both the expression of the haematopoietic oncogene lmo2 and the phosphorylation of H3Y41 at its promoter, while simultaneously increasing the binding of HP1alpha at the same site. Tauhese results identify a previously unrecognized nuclear role for JAK2 in the phosphorylation of H3Y41 and reveal a direct mechanistic link between two genes, jak2 and lmo2, involved in normal haematopoiesis and leukaemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783980      PMCID: PMC3785147          DOI: 10.1038/nature08448

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  30 in total

1.  Activated Jak2 with the V617F point mutation promotes G1/S phase transition.

Authors:  Christoph Walz; Brian J Crowley; Heidi E Hudon; Jessica L Gramlich; Donna S Neuberg; Klaus Podar; James D Griffin; Martin Sattler
Journal:  J Biol Chem       Date:  2006-04-21       Impact factor: 5.157

Review 2.  The myeloproliferative disorders.

Authors:  Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

3.  Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells.

Authors:  Loïc Garçon; Christine Rivat; Chloé James; Catherine Lacout; Valérie Camara-Clayette; Valérie Ugo; Yann Lecluse; Annelise Bennaceur-Griscelli; William Vainchenker
Journal:  Blood       Date:  2006-05-09       Impact factor: 22.113

4.  Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain.

Authors:  A J Bannister; P Zegerman; J F Partridge; E A Miska; J O Thomas; R C Allshire; T Kouzarides
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  TFBScluster: a resource for the characterization of transcriptional regulatory networks.

Authors:  Ian John Donaldson; Michael Chapman; Berthold Göttgens
Journal:  Bioinformatics       Date:  2005-04-26       Impact factor: 6.937

7.  JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

Authors:  Isabelle Plo; Mayuka Nakatake; Laurent Malivert; Jean-Pierre de Villartay; Stéphane Giraudier; Jean-Luc Villeval; Lisa Wiesmuller; William Vainchenker
Journal:  Blood       Date:  2008-05-30       Impact factor: 22.113

8.  Heterochromatin links to centromeric protection by recruiting shugoshin.

Authors:  Yuya Yamagishi; Takeshi Sakuno; Mari Shimura; Yoshinori Watanabe
Journal:  Nature       Date:  2008-09-11       Impact factor: 49.962

9.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

10.  HP1alpha guides neuronal fate by timing E2F-targeted genes silencing during terminal differentiation.

Authors:  Irina Panteleeva; Stéphanie Boutillier; Violaine See; Dave G Spiller; Caroline Rouaux; Geneviève Almouzni; Delphine Bailly; Christèle Maison; Helen C Lai; Jean-Philippe Loeffler; Anne-Laurence Boutillier
Journal:  EMBO J       Date:  2007-07-12       Impact factor: 11.598

View more
  290 in total

Review 1.  Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Authors:  Su-Jiang Zhang; Omar Abdel-Wahab
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.

Authors:  Gary W Reuther
Journal:  Am J Cancer Res       Date:  2011-05-29       Impact factor: 6.166

Review 3.  Using DNA methylation to understand biological consequences of genetic variability.

Authors:  Dena G Hernandez; Andrew B Singleton
Journal:  Neurodegener Dis       Date:  2011-11-26       Impact factor: 2.977

Review 4.  The Jak/STAT pathway.

Authors:  Douglas A Harrison
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-03-01       Impact factor: 10.005

Review 5.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

6.  Activation of estrogen receptor α by raloxifene through an activating protein-1-dependent tethering mechanism in human cervical epithelial cancer cells: a role for c-Jun N-terminal kinase.

Authors:  Elizabeth A Fogarty; Christina K Matulis; W Lee Kraus
Journal:  Mol Cell Endocrinol       Date:  2011-09-22       Impact factor: 4.102

Review 7.  A peek into the complex realm of histone phosphorylation.

Authors:  Taraswi Banerjee; Debabrata Chakravarti
Journal:  Mol Cell Biol       Date:  2011-10-17       Impact factor: 4.272

8.  Epigenetics and mutations in chronic myeloproliferative neoplasms.

Authors:  Alessandro M Vannucchi; Flavia Biamonte
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

Review 9.  Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Authors:  Sara C Meyer; Ross L Levine
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

10.  Intrinsic resistance to JAK2 inhibition in myelofibrosis.

Authors:  Anna Kalota; Grace R Jeschke; Martin Carroll; Elizabeth O Hexner
Journal:  Clin Cancer Res       Date:  2013-02-05       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.